Clinical Trials
52 trialsNCT03899987 2026-05-05
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
Roswell Park Cancer Institute
Phase 2 Active not recruiting
NCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
NCT04379518 2026-01-13
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT05756166 2025-06-24
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT06137950 2025-04-03
Interferon Alpha Therapy for Cervical CINI and HPV Infection
Mongolian National University of Medical Sciences
Phase 1 Completed
NCT00452023 2024-12-11
Pegasys® in Patients With Myeloproliferative Diseases
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00002965 2023-12-22
Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01545141 2023-10-27
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT04081389 2023-09-11
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT03599453 2023-07-18
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Completed
NCT01359956 2023-04-11
SICOG 0109
National Cancer Institute, Naples
Phase 3 Completed
NCT03403634 2022-03-02
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Roswell Park Cancer Institute
Phase 2 Completed
NCT04072263 2021-04-01
OVACURE
Leiden University Medical Center
Phase 1/2 Unknown
NCT02339324 2021-02-24
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
University of Pittsburgh
Phase 1 Completed
NCT02151448 2020-07-20
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
University of Pittsburgh
Phase 1/2 Completed
NCT01100528 2019-02-26
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01731158 2019-02-06
BERAT
Central European Society for Anticancer Drug Research
Phase 2 Completed
NCT00038376 2018-10-29
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00085436 2018-06-26
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT02185261 2018-06-07
Interferon α for the Therapy of Minimal Residual Disease
Peking University People's Hospital
Phase NA Unknown
NCT00854581 2018-04-17
Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma
University of Miami
Phase 4 Terminated
NCT01943422 2018-04-03
12-107
University of Pittsburgh
Phase 1 Completed
NCT00006244 2017-07-12
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01409174 2017-05-31
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00204529 2017-05-03
Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB
University Hospital Tuebingen
Phase 3 Completed
NCT02568241 2016-09-29
IDPR-HSCT
Peking University People's Hospital
Phase 1/2 Unknown
NCT00050531 2016-05-11
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00082719 2015-05-14
Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01462773 2015-01-13
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01274273 2014-12-02
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
University of Aarhus
Phase 2 Unknown
NCT02159482 2014-07-25
Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines
Duke University
Phase 2 Terminated
NCT01639885 2014-01-07
CHIP
Leiden University Medical Center
Phase 1/2 Completed
NCT00138151 2013-11-20
Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00502034 2013-07-10
Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3 Completed
NCT00619268 2013-02-15
TORAVA
Centre Leon Berard
Phase 2 Completed
NCT01404936 2013-02-01
Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00970996 2013-01-03
BCAA
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00227656 2012-12-11
Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00416429 2012-09-26
Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Centre Leon Berard
Phase 3 Completed
NCT01158534 2012-08-07
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00962715 2012-08-03
Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00504140 2012-08-02
Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00003239 2012-07-30
Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00068575 2012-02-15
Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00908869 2012-01-30
METRO1
Institut Paoli-Calmettes
Phase 1 Completed
NCT00561912 2011-12-26
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00002882 2011-12-13
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00178763 2011-03-03
FR-WB-TT
The University of Texas Health Science Center, Houston
Phase 2 Unknown
NCT00963664 2009-09-09
Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
NeoPlas Innovation
Phase 2 Withdrawn
NCT00308607 2009-04-03
Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
University of Turku
Phase 2 Completed